anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An acid addition salt of a ROR? regulator. Specifically relating to the acid addition salt of the compound of formula II. More specifically relating to benzoate, oxalate, methanesulfonate, maleate, hydrobromate, hydrochloride salt, and acetate of the compound of formula II and the benzoate crystal form, benzoate amorphous form, oxalate crystal form, oxalate amorphous form, methanesulfonate amorphous form, maleate B crystal form, maleate C crystal form, maleate D crystal form, hydrobromate I crystal form, hydrochloride salt ? crystal form, hydrochloride salt ? crystal form, hydrochloride salt ? crystal form, and acetate crystal form of the compound of formula II.
Subjects will be administered GSK3050002 intravenously (IV) over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion. On Day 1, loading dose of GSK3050002 10 milligrams per kilogram (mg/kg) will be administered intravenously, followed by maintenance doses of 5mg/kg IV administered at Day 15 and Day 29. Each subject will receive a cumulative dose of 20 mg/kg.
OBJECTIVE: To investigate the relationship between both self-reported and objective sleep variables and low-grade inflammation in children and adolescents with major depressive disorder (MDD) of moderate to severe symptom severity.
METHODS: In this cross-sectional study, we examined twenty-nine children and adolescents diagnosed with MDD and twenty-nine healthy controls (HC). Following a one-week actigraphy assessment, comprehensive sleep evaluations were conducted, including a one-night sleep EEG measurement and self-reported sleep data. Plasma high-sensitivity C-reactive protein (hsCRP) was employed as a marker to assess low-grade inflammation.
RESULTS: No significant difference in hsCRP levels was observed between participants with MDD and HC. Furthermore, after adjusting for sleep difficulties, hsCRP exhibited no correlation with the severity of depressive symptoms. In HC, levels of hsCRP were not linked to self-reported and objective sleep variables. In contrast, depressed participants showed a significant correlation between hsCRP levels and increased subjective insomnia severity (Insomnia Severity Index; r = 0.41, p < 0.05), increased time spent in the N2 sleep stage (r = 0.47, p < 0.01), and decreased time spent in slow-wave sleep (r = - 0.61, p < 0.001). Upon additional adjustments for body mass index, tobacco use and depression severity, only the inverse association between hsCRP and time spent in slow-wave sleep retained statistical significance. Moderation analysis indicated that group status (MDD vs. HC) significantly moderates the association between slow-wave sleep and hsCRP.
CONCLUSION: Our findings suggest that alterations in the architecture of slow-wave sleep may have a significant influence on modulating low-grade inflammatory processes in children and adolescents with MDD.
Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 1 uses 40 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
Participants will receive a brief smoking cessation intervention based on the asking about tobacco use, Advising smokers to quit, Assessing their willingness to quit,Assisting in quitting, and Arranging for follow-up and relevance, risks, rewards, roadblocks and repetition models at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
The utility model discloses a senile plaque removal plaster easy and convenient to use. The senile plaque removal plaster is characterized by comprising a medical proof fabric (1), an EVA foaming layer (2), salicylic acid phenol ointment (3) and SOD honey (5). The EVA foaming layer (2) is arranged on the medical proof fabric (1). The salicylic acid phenol ointment (3) is arranged in the middle of the EVA foaming layer (2). The SOD honey (5) is arranged on the salicylic acid phenol ointment (3). The senile plaque removal plaster easy and convenient to use has the advantages that the EVA foaming layer is fixed through the medical proof fabric, treatment medicine is located at the treatment point of the senile plaque, the EVA foaming layer is adopted, and therefore hole shearing, medicine placement and medicine sealing can be conveniently carried out according to the size of the senile plaque; the salicylic acid phenol ointment is adopted to treat the keratosis of the senile plaque, namely the melanocyte, the penetrating capacity is high, and the irritant is low; the SOD honey is adopted to relieve the irritant of the salicylic acid phenol ointment, harmful substances generated in the metabolism are removed, the dermatomyositis is prevented and treated, skin aging resistance is achieved, and the senile plaque is effectively removed.
The invention discloses an oxidation/pH dual-response curcumin prodrug and a preparation method thereof, belonging to the field of biomedical high polymer materials. According to the invention, quaternary ammonium salt hydroxyethyl starch is used as a hydrophilic framework, and 3,3' -dithiodipropionic acid is coupled to hydroxyl of the quaternary ammonium salt hydroxyethyl starch through esterification reaction to obtain an intermediate; and then the phenolic hydroxyl of the curcumin and the carboxyl end of the intermediate are subjected to esterification reaction to generate the quaternary ammonium salt hydroxyethyl starch-curcumin prodrug. The curcumin prodrug can be synthesized by a two-step esterification method, and the preparation process is simple. Meanwhile, the prodrug can self-assemble in water to form a stable nano micelle structure, and can improve the solubility of the drug and the enrichment capacity of the drug at tumor positions. The prodrug can rapidly release curcumin under the environment containing active oxygen or weak acidity, and shows good dual responsiveness of active oxygen and pH. The prodrug can effectively inhibit proliferation of tumor cells, and has a certain application prospect in cancer treatment.
One of the most devastating diseases of apples is scab, caused by the fungus Venturia inaequalis. Most commercial apple varieties are susceptible to this disease; only a few are resistant. Breeding approaches are being used to develop better apple varieties that are resistant to scab. Volatile organic compounds (VOCs) contribute greatly to a plant's phenotype, and their emission profile largely depends on the genotype. In the non-destructive phenotyping of plants, VOCs can be used as biomarkers. In this study, we assessed non-destructively the scab tolerance potential of resistant (cv. 'Prima') and susceptible (cv. 'Oregon Spur') apple cultivars by comparing their major leaf VOC compositions and relative proportions. A comparison of the leaf VOC profiles of the two cultivars revealed 16 different VOCs, with cis-3-hexenyl acetate (3HA) emerging as a biomarker of cultivar differences. V. inaequalis growth was significantly inhibited in vitro by 3HA treatment. 3HA was significantly effective in reducing scab symptoms on V. inaequalis-inoculated leaves of 'Oregon Spur.' The resistant cultivar 'Prima' also exhibited higher lipoxygenase (LOX) activity and α-linolenic acid (ALA) levels, suggesting that V. inaequalis resistance is linked to LOX activity and 3HA biosynthesis. This study proposes 3HA as a potential biomarker for rapid non-destructive screening of scab-resistant apple germplasm of 'Prima' based on leaf VOCs.
* Methotrexate Injection is available as a solution at a concentration of a 100 mg/mL. Verify the concentration prior to preparation and administration to avoid overdosage.
  * Methotrexate Injection is a hazardous drug. Follow applicable special handling and disposable procedures. 1
  * Methotrexate Injection may be further diluted immediately before use with an appropriate sterile, preservative-free medium such as 5% Dextrose Solution, USP or Sodium Chloride Injection, USP. 
  * Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Introduction. Chronic urticaria is an inflammatory skin condition characterized by the presence of evanescent wheals or angioedema that last for ≥ 6 weeks. Objective. To determine the prevalence of urticaria and describe its clinical characteristics in children and adolescents under 19 years of age in a general hospital. Population and methods. This was a cross-sectional study carried out between 2015 and 2020 in a population of children and adolescents seen at a private healthcare facility. Results. A total of 1567 medical records of patients with urticaria seen during the study period were reviewed. Thirty-six patients with chronic urticaria were identified; the prevalence was 0.16% (95% CI: 0.11-0.22). Conclusion. The prevalence of chronic urticaria in children and adolescents was 0.16%. A higher frequency was observed among girls and adolescents.
BACKGROUND AND OBJECTIVE: COPD and bronchiectasis are common causes of morbidity, particularly around exacerbation. Colonisation with respiratory pathogens can increase the frequency and severity of exacerbations. However, bacterial and viral presence at exacerbation in people with airway colonisation has not been well studied.
METHODS: A 6-month cohort study of participants (n = 30) with chronic bronchitis due to bronchiectasis (n = 26) and/or COPD (n = 13) and colonisation with Pseudomonas aeruginosa or Haemophilus influenzae was proven on two sputum cultures at exacerbation in the previous 12 months. Participants were provided self-management education and collected sputum samples daily. Sputum samples at baseline (at least 14 days before or after an exacerbation) and at each exacerbation were examined for a panel of 34 respiratory pathogens using commercially available RT-PCR kits and compared to results obtained using culture methods for the detection of bacteria.
RESULTS: Participants provided 29 baseline samples and 71 samples at exacerbation. In 17/29 baseline samples, RT-PCR analysis confirmed the organism demonstrated by culture, while 12 samples showed a discrepancy from culture results. Most exacerbations (57.7%) were not associated with acquiring new bacteria or viruses, while 19.8% showed new bacteria, 15.7% new viruses and 7% both new viruses and bacteria.
CONCLUSION: Over half of exacerbations were not associated with new organisms in this cohort of participants with chronic bronchitis and colonisation. However, 26.8% demonstrated a new bacterial species in sputum, which is relevant for antibiotic therapy. Baseline RT-PCR and culture results were discordant in one-third of participants.
The invention relates to a traditional Chinese medicine composition for treating coronary heart disease angina. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 7-13 parts of frankincense, 17-23 parts of lignum dalbergiae odoriferae, 7-13 parts of panax pseudoginseng and 2-8 parts of borneol. The invention also provides an application of the traditional Chinese medicine composition in treating coronary heart disease angina. The traditional Chinese medicine composition provided by the invention belongs to a traditional Chinese medicine compound preparation, and the compatibility meets the principle of chief, deputy, assistant and envoy of the traditional Chinese medicine. According to the verification of a pharmacodynamic experiment, the traditional Chinese medicine composition has a perfect curative effect on a patient suffering coronary heart disease angina, and a new method is provided for treating coronary heart disease angina. By applying the traditional Chinese medicine composition to acupuncture points, the medicine is absorbed by the skin and stimulates the meridians and acupuncture points, and the interference and degradation effects of the first-pass effect of the liver and gastrointestinal tract factors as well as possible toxic and side effects caused by oral administration of the medicine are avoided, thus the traditional Chinese medicine composition has a perfect application prospect.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of retaining effects and having good cosmetic characteristics without any change in volume of each phase with time by including a specific volatile fluoro-oil in one phase in a composition for a multiphase cosmetic. SOLUTION: This composition comprises at least one kind of volatile fluoro- oil having >1, preferably >1.2 density in one phase in a composition for a multiphase cosmetic in the form of separate fluid phases. The phase comprising the volatile fluoro-oil constitutes the lower phase of the abode composition and the ratio of the volatile fluoro-oil is preferably 10-100 wt.% in the lower phase. For example, a perfluorocycloalkyl represented by the formula (n) is 4 or 5; (m) is 1 or 2; (p) is 1-3) (e.g. perfluoromethylcyclopentane) is cited as the volatile fluoro-oil. When the composition is in the two-phase form the upper phase is preferably composed of either one of an immiscible oily phase (e.g. a mineral, a vegetable or a synthetic oil) and an aqueous phase (e.g. sterilized desalted water or blossom-water).
PURPOSE: An oral cleansing composition containing GMCSF(granulocyte-macrophage colony stimulating factor) is provided to enhance immunity and to treat stomatitis. CONSTITUTION: An oral cleansing composition for enhancing immunity contains GMCSF(granulocyte-macrophage colony stimulating factor) and disinfectant as an active ingredient. The GM-CSF is natural or recombinant GM-CSF. The recombinant GM-CSF is derived from plants, animals, bacteria, or fungi. The disinfectant is benzethonium chloride or chloride cetyl pyridinium. The oral cleansing composition is manufactured in the form of an oral cleansing solution, spray, or paste.
More than 250 million courses of antibiotics are prescribed annually in the ambulatory care setting in the United States alone, including more than 40 million in children under 18 years of age. The perception that antibiotic use has minimal attendant adverse side effects contributes to the over-utilization of antibiotics in clinical circumstances when they are not strictly indicated. We have learned much about the human microbiome. The emerging view is of profound life-long bi-directional interactions between our microbiota and our cells. Perturbations in the microbiota affect metabolic, immune, and cognitive physiology in experimental animal models. When a person takes an antibiotic, the antibiotic diffuses via the blood into all body compartments, selecting for resistance. We propose to examine the effects of two commonly used antibiotics (the beta-lactam, amoxicillin and the macrolide azithromycin) on human microbial populations and on metabolic and immune physiology, studying healthy human volunteers in a randomized controlled clinical trial at the NIH Clinical Center. Our hypothesis is that in addition to acutely perturbing the human microbiome, these agents will have measurable metabolic and immunologic effects, with residual effects in the weeks that follow. To test this hypothesis, we will assess the effects of a brief therapeutic course of antibiotics on microbiome and metagenome composition. After an initial evaluation period, antibiotics will be given for 7 days or 5 days (depending on the antibiotic), and there will be a post-treatment evaluation. A control group will receive no drug intervention. Specimens will be obtained from multiple sites at each of 10 time points occurring before, during, and after antibiotic administration, and used for estimating bacterial and fungal composition and gene content. We will also assess the effects of the antibiotic course on markers of innate and adaptive immunity as well as markers of metabolic and hormonal physiology. A subgroup of subjects will be studied in the Clinical Center metabolic chamber to assess 24-hour energy expenditure and its components (sleeping, diet-induced, and activity energy expenditure), as well as macronutrient oxidation rates (carbohydrate, fat, and protein), during 3 of the 10 study visits. In addition to the primary data analyses, we will build a model that integrates the temporal data to begin to understand the complex intertwined physiology between microbiome and host.
<P>PROBLEM TO BE SOLVED: To realize Alpinia speciosa vinegar capable of more effectively exhibiting the effect and utilize coal of Alpinia speciosa left after dry distillation or bagasse coal after squeezing sugarcane as a soil-improving agent in regard to vinegar of Alpinia speciosa collected from smoke by dry-distilling Alipinia speciosa and a method for utilizing the Alipinia speciosa vinegar.  <P>SOLUTION: The stem of Alpinia speciosa in which at least outer skin part is dried is put in a dry distillation oven and dry-distilled and the Alpinia speciosa vinegar is collected from smoke generated in this time. Coal left after dry distillation is used as the soil-improving material, etc. The Alpinia speciosa vinegar collected from smoke is formulated with pyroligneous acid or bamboo vinegar to provide an Alpinia speciosa vinegar product. The Alpinia speciosa vinegar or the other liquid is impregnated into Alpinia speciosa coal or sugarcane bagasse coal obtained by dry-distilling the stem of Alpinia speciosa or sugarcane bagasse and the impregnated material is used as the soil-improving material or a material for insect proof.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
This invention relates to topical lubricants that can be spread  across  the  surfaces  of  the  genitals  during  sexual intercourse,  to reduce the risk of  infection by the human immunodeficiency virus (HIV, the virus that causes AIDS). The anti-HIV lubricants of this invention contain a non-toxic, non-irritating, water-soluble zinc salt that can directly inhibit the infectivity of HIV virus particles and reduce the risk of infection even in users who do not suffer from genital lesions caused by other diseases, such as genital herpes or syphilis. Suitable zinc salts include zinc acetate, zinc propionate, and other non-irritating water-soluble organic salts of zinc that readily dissociate into ionic form when dissolved in water (dissociation levels preferably should be equal to or higher than the dissociation rate of zinc gluconate in water). Free zinc,  in  cationic  form  (Zn++),  is  believed  to  reduce  the infectivity of HIV virus particles by forming crosslinking bonds with cysteine or histidine residues in the gp120 protein of HIV. Inside a vaginal cavity, these crosslinking bonds can cause HIV particles to bind in a more or less random manner to other viral particles, to proteins in vaginal fluids, and to proteins on the surfaces of epidermal or epithelial cells that will soon be sloughed off  from the genital  surfaces.  This cross-linking activity eliminates or reduces the infectivity of HIV particles. A two-step incubation assay is also disclosed for evaluating candidate anti-HIV agents for use in topical lubricants. A brief first incubation step models agent-virus interactions inside a vagina,  after  intercourse. The agent/virus mixture  is then dliuted to suitable levels before HIV-susceptible lymphocytes are added and incubated in a second, much longer incubation step.
FIELD: biochemistry and medicine. SUBSTANCE: derivatives of pyrimidine-4-one of formula 1 at definite values of radicals, or their PHARMACEUTICALLY acceptable salts possessing serotonin-antagonistic, dopamine-antagonistic and antihistamine activities and composition containing said derivatives of pyrimidine-4-one and inert carrier. Reagent 1: compound of formula 11. Reagent 2: compound of formula lll, where W=N is reaction split-off group at respective said values of radicals. Process is conducted in inert solvent in presence of base. Compound structures of formulas l, ll and lll are given in invention description. EFFECT: higher efficiency.
The invention provides use of fritillaria cirrhosa total alkaloids in preparing drugs for inhibiting multiplication of eukaryote tumor cells. The invention also provides new cancer-resisting use of compounds in fritillaria cirrhosa. The fritillaria cirrhosa total alkaloids can inhibit the multiplication of the eukaryote tumor cells, has an effect on curing tumors and can be used for curing multiple tumors. With the same dose, the drug effect of the fritillaria cirrhosa total alkaloids is obviously better than the compound peimine and peiminine. The fritillaria cirrhosa total alkaloids have stable quality, are safe to use and are easy to control, the preparation method is simple, and the mass production and clinical use can be conveniently realized. Monomeric compounds such as chuanbeinone, kashmirine, imperialine-beta-N-oxside, isoverticine, isoverticine-beta-N-oxide and peimisine contained in the fritillaria cirrhosa total alkaloids also can inhibit the multiplication of the eukaryote tumor cells and have an effect on curing the tumor; and with the same dose, the drug effect of the monomeric compounds in the fritillaria cirrhosa total alkaloids is obviously better than that of peimine and peiminine, and a new choice for clinically curing the tumor is provided.
Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their typical level of physical activity. After the baseline visit, participants will reduce their step count by more than half for two weeks. Participants will visit the laboratory once every week during the 2 week interventional period for a total of 3 visits.
Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
Organ transplantation is an effective treatment for several end-stage organ diseases. Preventing rejection of transplanted organs remains the premier challenge. According to the humoral theory, donor specific antibodies (DSA) are the major cause of chronic rejection and allograft loss. Despite this, and evidence that links human leukocyte antigen (HLA) antibodies to allograft dysfunction and loss, doubt remains about the cause-and-effect relationship and confirmation of this evidence is necessary to help facilitate change in transplant practice. Prospective monitoring for de novo DSA in the serum of patients who have received a transplant may allow for earlier detection, evaluation, and characterization of factors leading to the development of antibodies prior to the development of clinical manifestations of graft dysfunction.

The contribution of the major histocompatibility complex (MHC) Class I and Class II antibodies to transplant outcomes is well documented. However, there is emerging evidence that antibody mediated rejection and the severity of outcomes may involve proteins and antibodies that go beyond HLA Class I and II. A number of assays are available for testing for these additional antibodies and proteins but they are currently not used for widespread patient monitoring in part due to lack of data justifying their commercial use. This pilot study will prospectively evaluate for the presence and/or emergence of these unique antibodies, (I.E. MICA antigen, IgG3 and C1Q) in serial samples of serum, and confirm or reject the utility of incorporating these assays into routine patient monitoring which might provide earlier evidence of emerging rejection. Serum samples will be stored indefinitely for future kidney transplant research projects.